CDKN2B-AS1 and urinary bladder carcinoma: For example, ANRIL overexpression was found in bladder cancer [52], prostate carcinoma [50], ovarian cancer [53], cervical cancer [54], breast cancer [55], gastric cancer [56], esophageal squamous cell carcinoma [57], lung cancer [58], and hepatocellular carcinoma [59].